Abstract
In order to compare the adjuvant activity of compound mucosal immune adjuvant (cMIA), two novel compound adjuvants (cMIA I and cMIA II) were prepared and mixed with Newcastle-disease (ND) vaccine, respectively, to vaccinate 7-day-old chickens, taking the non-adjuvant vaccines and PBS as controls. Serum were sampled on weeks 1–7 and tissues on weeks 3, 5 and 7 after vaccination, respectively. The humoral and cellular immune responses were determined by means of hemagglutination inhibition test, enzyme linked immunosorbent assay, semi-quantitative RT-PCR, immunohistochemical examination and histological examination. The results showed that two compound adjuvants could promote CD3+ T lymphocytes, IgA secreting cells, intestinal intraepithelial lymphocytes (iIEL) and Mast cells formation and enhance serum and content antibody titer. The best adjuvant activity of cMIA II in promoting cellular immunity and cMIA I in enhancing humoral immunity occurred in whole immune period. Based on good synergistic effects of their components, two cMIAs would be expected as new-type mucosal immune adjuvants for mucosal immune.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
